Literature DB >> 3803584

Antithrombin properties of C-terminus of hirudin using synthetic unsulfated N alpha-acetyl-hirudin45-65.

J L Krstenansky, S J Mao.   

Abstract

Unsulfated N alpha-acetyl-hirudin45-65 (MDL 27 589), which corresponds to the C-terminus of hirudin1-65, was synthesized by solid-phase methods. The synthetic peptide was able to inhibit fibrin formation and the release of fibrinopeptide A from fibrinogen by thrombin. The catalytic site of thrombin was not perturbed by the synthetic peptide as H-D-Phe-Pip-Arg-pNA hydrolysis (amidase activity) was not affected. The binding of synthetic peptide and thrombin was assessed by isolation of the complex on gel-filtration chromatography. A single binding site with a binding affinity (Ka) of approx. 1.0 X 10(5) M-1 was observed for thrombin-hirudin45-65 interaction. The data suggest that the C-terminal residues 45-65 of hirudin contain a binding domain which recognizes thrombin and yet does not bind to the catalytic site of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3803584     DOI: 10.1016/0014-5793(87)81264-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  Counteracting effect of glycyrrhizin on the hemostatic abnormalities induced by Bothrops jararaca snake venom.

Authors:  Mariane Assafim; Marcos S Ferreira; Flávia S Frattani; Jorge A Guimarães; Robson Q Monteiro; Russolina B Zingali
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 2.  Hirudin, a new therapeutic tool?

Authors:  J Bichler; H Fritz
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

3.  Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex.

Authors:  G De Simone; A Lombardi; S Galdiero; F Nastri; R Della Morte; N Staiano; C Pedone; M Bolognesi; V Pavone
Journal:  Protein Sci       Date:  1998-02       Impact factor: 6.725

4.  Prediction of location of active sites in biologically active peptides.

Authors:  T Kikuchi
Journal:  J Protein Chem       Date:  1996-08

5.  Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human alpha-thrombin.

Authors:  J Féthière; Y Tsuda; R Coulombe; Y Konishi; M Cygler
Journal:  Protein Sci       Date:  1996-06       Impact factor: 6.725

6.  Characterization of bothrojaracin interaction with human prothrombin.

Authors:  R Q Monteiro; P E Bock; M L Bianconi; R B Zingali
Journal:  Protein Sci       Date:  2001-09       Impact factor: 6.725

7.  Thrombin-specific inhibition by and slow cleavage of hirulog-1.

Authors:  J I Witting; P Bourdon; D V Brezniak; J M Maraganore; J W Fenton
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

8.  Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons.

Authors:  Y Cadroy; J M Maraganore; S R Hanson; L A Harker
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

9.  The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand.

Authors:  Amanda J Boyle; Leigh Ann Roddick; Varsha Bhakta; Melissa D Lambourne; Murray S Junop; Patricia C Liaw; Jeffrey I Weitz; William P Sheffield
Journal:  BMC Biochem       Date:  2013-03-07       Impact factor: 4.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.